Glucotrack, Inc. (NASDAQ: GCTK) shares began Thursday substantially lower. The Rutherford, New Jersey-based company, a medical device concern focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company’s continuous blood glucose monitoring (CBGM) platform.
The patents strengthen Glucotrack’s competitive position and intellectual property protection as the Company advances its multi-year, fully implantable CBGM system toward commercialization.
The three patents protect key technologies in Glucotrack's CBGM system, a long-term implantable device designed for multi-year sensor longevity, including proprietary sensor chemistry, intravascular lead design, and low-power electronics.
Together, according to the news release from this morning, “these innovations bridge the gap between short-lived subcutaneous sensors and larger pacemaker-class devices.
“These patents represent a significant milestone in protecting our innovative technology that is at the core of our CBGM system,” said CEO Paul V. Goode.
“Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization.
These patents establish important competitive barriers and strengthen our position to deliver a differentiated approach to diabetes management.”
GCTK shares slipped 71 cents, or 20.8%, to $2.70.
